FDA to share drug approval packages with foreign regulators

Advertisement

The FDA has launched the Global Reliance Disclosure Program, which allows drug and biologic applicants to share the agency’s minimally redacted approval packages with health authorities outside the U.S. The goal is to allow foreign regulators to rely on the FDA’s reviews instead of conducting duplicate evaluations while retaining their own authority over regulatory decisions.

The program began Oct. 30 with a PEPFAR tentative approval for lenacapavir, a drug for HIV prevention and treatment, and is currently available only for products with PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug applications. The FDA said it intends to expand the program in January 2027 to all novel drugs and biologics, including new molecular entity applications and original biologics license applications, according to a Nov. 17 news release.

The agency said patients in many parts of the world wait months or years longer for access to medicines because their national regulators have limited capacity to complete independent reviews.

To participate, applicants must request to join within 10 calendar days of approval and confirm the package is being submitted to a foreign regulator in support of a marketing application, the FDA said. Eligible applicants will receive details in their approval letters, and the agency intends to provide the minimally redacted package on an expedited basis. Requests for approval packages for other purposes will not be processed under the program and should go through the Freedom of Information Act. The FDA also plans to launch a pathway in early 2027 to expedite requests for minimally redacted action packages for drugs and biologics already approved.

Advertisement

Next Up in Pharmacy

Advertisement